Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IDEAYA Biosciences Inc.

www.ideayabio.com

Latest From IDEAYA Biosciences Inc.

Finance Watch: Three New Biopharma IPOs In The US With Eight More Entering The Queue

Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.

Financing Business Strategies

IPO Update: Pace Of US Offerings Slows As 13 Biopharmas Go Public In 2019

With about three IPOs per month compared with a pace of nearly six per month in 2018, drug developers have raised $1.55bn with US offerings this year – though returns have been mixed.

Financing Business Strategies

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs

Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.

Deals Business Strategies

Immuno-Oncology: Unicorns, China And The Perfect Storm

There is a unique phenomenon being realized in immuno-oncology deal-making compared with other segments in the life sciences sector – an apparent uncoupling between risk and return on invested capital, as early assets provide similar liquidity to more mature assets.

ImmunoOncology Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • IDEAYA Biosciences Inc.
  • Senior Management
  • Yujiro S Hata, CEO
    Paul A Stone, CFO
    Michael Dillon, PhD, SVP, CSO & Head, Research
    Julie Hambleton, MD, SVP, CMO & Head, Dev.
  • Contact Info
  • IDEAYA Biosciences Inc.
    Phone: (650) 443-6209
    7000 Shoreline Ct.
    Ste. 350
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register